Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Amyotrophic Lateral Sclerosis: early-phase trial registry
47 of 103 indexed Amyotrophic Lateral Sclerosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #130 of 28,707 conditions by registered trial count.
103 US clinical trials · 47 currently recruiting · #130 of 28,707 conditions by registered trial count
Amyotrophic Lateral Sclerosis: 103 US clinical trials tracked, 47 recruiting.
Amyotrophic Lateral Sclerosis is the subject of 103 registered US clinical trials on ClinicalTrials.gov, 47 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most active sponsor is University of Miami, running 7 of these trials.
Enrollment posture brief
Registry condition amyotrophic-lateral-sclerosis
OPEN 47 | RECR 46% | LATE 6 | EARLY 40 | RANK #130 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Endothelial Dysfunction (46% recruiting · 46 trials)
Amyotrophic Lateral Sclerosis lists 47 open slots (46% of 103 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Amyotrophic Lateral Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Amyotrophic Lateral Sclerosis is recruiting above its size-band peers.
47 of 103 indexed trials (45.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Amyotrophic Lateral Sclerosis trials is spread across many organizations.
University of Miami accounts for 7 of 103 trials (6.8%). 69 distinct sponsors appear on at least one study for this condition label.
-
Most Amyotrophic Lateral Sclerosis trials plan to enrol fewer than 100 people.
Median target enrolment is 66 among the 103 trials that report a genuine target (sentinel values excluded). 62 of those (60.2%) plan for fewer than 100 participants.
-
Amyotrophic Lateral Sclerosis splits between interventional and observational designs.
68 interventional and 35 observational studies make up this index (66% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
103 total, page 2 of 3
Phenotype, Genotype and Biomarkers 2
University of Miami
NCT04875416
Remote Speech and Swallowing Assessment in ALS
Milton S. Hershey Medical Center
NCT04889898
PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis
University of Miami
NCT01508962
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Ionis Pharmaceuticals
NCT04768972
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
Mayo Clinic
NCT03268603
Regulatory T Cells for Amyotrophic Lateral Sclerosis
Cellenkos
NCT05695521
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
Woolsey Pharmaceuticals
NCT05218668
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
National Institute of Neurological Disorders and Stroke (NINDS)
NCT07204977
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
UniQure Biopharma B.V.
NCT06100276
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
Cedars-Sinai Medical Center
NCT05306457
COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis
Synchron Medical
NCT05035823
Study in ALS With Abatacept & IL-2
The Methodist Hospital Research Institute
NCT06307301
Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS
n-Lorem Foundation
NCT06392126
Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS
n-Lorem Foundation
NCT06977451
Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS
n-Lorem Foundation
NCT07095712
Amyotrophic Lateral Sclerosis Web Based Patient Care Database: ALSConnection.Org
Forbes Norris MDA/ALS Research Center
NCT00302198
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
Cytokinetics
NCT01709149
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
Novartis Pharmaceuticals
NCT00072709
Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life
Johns Hopkins University
NCT01160367
Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases
Nemours Children's Clinic
NCT02532244
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
Biogen
NCT02623699
Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation
Edward Kasaraskis
NCT00116558
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
Neuraltus Pharmaceuticals
NCT02794857
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Neuraltus Pharmaceuticals
NCT01281631
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Forbes Norris MDA/ALS Research Center
NCT00790582
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
Avanir Pharmaceuticals
NCT00021697
Open Label Extension Study of AMX0035 in Patients With ALS
Amylyx Pharmaceuticals
NCT03488524
The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2)
Massachusetts General Hospital
NCT04051333
Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)
Knopp Biosciences
NCT00931944
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
AL-S Pharma
NCT05039099
Multiple Doses of AT-1501-A201 in Adults With ALS
Anelixis Therapeutics
NCT04322149
Virtual Seating Coach on Power Wheelchairs of Persons With Amyotrophic Lateral Sclerosis (ALS)
Wake Forest University Health Sciences
NCT05742828
Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis
University of Miami
NCT00706147
Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)
Wake Forest University Health Sciences
NCT00956501
ALS and Airway Clearance (ALSAC) Therapy
The University of Texas Health Science Center at San Antonio
NCT04947436
A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
Amylyx Pharmaceuticals
NCT04516096
Impact of Nuedexta on Bulbar Physiology and Function in ALS
University of Florida
NCT03883581
Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population
Drexel University College of Medicine
NCT00718497
Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis
Dwight Koeberl, M.D., Ph.D.
NCT04245709
Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)
Columbia University
NCT00537641
Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis
Mayo Clinic
NCT03793868
Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort
National Institute of Environmental Health Sciences (NIEHS)
NCT00377351
Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease
Duke University
NCT00324454
Cervical Electrical Stimulation for ALS
VA Office of Research and Development
NCT03411863
CNS10-NPC-GDNF for the Treatment of ALS
Cedars-Sinai Medical Center
NCT02943850
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
Helixmith Co.
NCT04632225
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
Massachusetts General Hospital
NCT05189106
Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis
University of Alabama at Birmingham
NCT05979688
Open Label Study: Treatment of ALS Fatigue With PolyMVA
University of Missouri-Columbia
NCT04557410
Cerebrospinal Fluid Repository
Drexel University College of Medicine
NCT00714636
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 21 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Amyotrophic Lateral Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Amyotrophic Lateral Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Amyotrophic Lateral Sclerosis page
103 registered trials, 47 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 47 Amyotrophic Lateral Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Miami sponsors the most Amyotrophic Lateral Sclerosis trials on record, review their full trial history before evaluating a specific study. See University of Miami's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Amyotrophic Lateral Sclerosis condition card totals 103 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.